康宁杰瑞(09966.HK)JSKN003治疗卵巢癌三期临床研究获批

阿斯达克财经
27 Dec 2024

康宁杰瑞-B(09966.HK) 公布,旗下靶向HER2双表位抗体药物偶联物(ADC)用于治疗卵巢癌的三期临床研究,已获国家药监局药品审评中心同意开展,该研究旨在比较JSKN003与研究者选择化疗在该患者人群中的疗效和安全性。

目前,JSKN003正在澳洲开展一期临床研究,以及在中国进行一期、二期和三期临床研究。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-24 12:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10